Mirum Pharmaceuticals, Inc.
MIRM
Rang în acțiuni
#3229
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Preț acțiune
$85.25
Capitalizare de piață
$5.54B
Schimbare (1 zi)
3.66%
Schimbare (1 an)
16.73%
Țară
US
Tranzacționează Mirum Pharmaceuticals, Inc. (MIRM)
Categorie
Healthcare
Raport P/B pentru Mirum Pharmaceuticals, Inc. (MIRM)
Raport P/B la data de October 2026 TTM: -486.22
Conform celor mai recente rapoarte financiare și prețului acțiunilor Mirum Pharmaceuticals, Inc., raportul P/B actual (TTM) este -486.22. La sfârșitul anului 2023, compania avea un P/B de 4.85.
Istoricul raportului P/B pentru Mirum Pharmaceuticals, Inc. din 2018 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
